Linus Backert
Immatics Biotechnologies (Germany)
ORCID: 0000-0002-1694-1396Also affiliated with University of Tübingen
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 3 papers. Top paper: “First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors”.
Tobias A.W. Holderried, Jason J. Luke, Van K. Morris, Winfried Alsdorf, Katrin Wetzko +27 more
Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner +36 more
Dejka M. Araujo, Manik Chatterjee, Apostolia M. Tsimberidou, Tobias A.W. Holderried, Amir A. Jazaeri +35 more